Updated

Updated · Investor's Business Daily · Aug 10

Hims Shares Tumble After 37-Cent Loss Swamps Q2 Sales Beat

Updated

Updated · Investor's Business Daily · Aug 10

Hims Shares Tumble After 37-Cent Loss Swamps Q2 Sales Beat

3 articles · Updated · Investor's Business Daily · Aug 10

Hims & Hers Health stock fell sharply late Monday after the company posted a 37-cent-per-share June-quarter loss, far worse than analysts' expected 5-cent loss.
That earnings miss overshadowed a second-quarter revenue beat and a raised outlook, shifting investor focus from top-line momentum to the scale of the loss.
Hims is known for its telehealth platform and for offering knockoff versions of Novo Nordisk's injectable semaglutide, a business line that has drawn close market attention.

Sources

Left17%

Center33%

Right50%

Investor's Business Daily10d ago

Hims Stock Falls After Reporting 37-Cent Per-Share Loss

Hims & Hers' shift to branded obesity drugs drives wider quarterly loss | Reuters

BNN Bloomberg9d ago

Hims & Hers shares slide

Why did Hims & Hers stock plunge despite record sales, and what hidden legal costs are truly spooking investors?

Will the regulatory crackdown on cheap compounded weight-loss drugs permanently destroy the profit margins of telehealth giants?

Can AI investments and global expansion save this telehealth platform from the crushing financial weight of DOJ and FTC scrutiny?

Related Stories

Sources

12 total

Left17%

Center33%

Right50%

Investor's Business Daily10d ago

Hims Stock Falls After Reporting 37-Cent Per-Share Loss

Hims & Hers' shift to branded obesity drugs drives wider quarterly loss | Reuters

BNN Bloomberg9d ago

Hims & Hers shares slide

Show all 12 sources

Related Stories